TriSalus Life Sciences to Present New Data at 2026 Radiology Conference

The company will showcase its novel delivery technology for solid tumor treatments.

Apr. 10, 2026 at 12:00am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the intricate internal structures of a human organ, conceptually representing the potential for targeted drug delivery to solid tumors.Novel drug delivery technology aims to overcome barriers and improve treatment outcomes for solid tumor cancers.Westminster Today

TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard cancer therapies, announced it will present new data at the 2026 Society of Interventional Radiology Annual Scientific Meeting. The presentations will focus on the company's Pressure-Enabled Drug Delivery (PEDD) technology, which aims to improve therapeutic delivery for patients with solid tumors.

Why it matters

TriSalus' PEDD technology represents a potential breakthrough in oncology, as improving drug delivery to solid tumors is a major challenge in cancer treatment. If successful, PEDD could lead to more effective therapies and better outcomes for patients.

The details

TriSalus will present data on its investigational immunotherapeutic and how the PEDD approach can be used to enhance the delivery of these treatments to solid tumors. The company believes PEDD has the potential to transform solid tumor treatment by overcoming barriers to effective drug delivery.

  • TriSalus will present the new data at the 2026 Society of Interventional Radiology Annual Scientific Meeting.

The players

TriSalus Life Sciences, Inc.

An oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors.

Got photos? Submit your photos here. ›

The takeaway

TriSalus' innovative PEDD technology represents a promising advancement in the fight against solid tumor cancers, as improving drug delivery is a critical challenge. If the data presented at the radiology conference is positive, it could pave the way for more effective solid tumor treatments in the future.